Tokai Pharmaceuticals (TKAI) has risen sharply, recording gains of 42.99% in the past 4 weeks. However, the stock has corrected -8.93% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 43.76% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 20.33% and the 50-Day Moving Average is 5.59%.The 200 Day SMA reached 71.12%
Tokai Pharmaceuticals (NASDAQ:TKAI): The stock opened in the green at $1.53 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $1.63 and a low of $1.46 for the day. The stock did not find buyers even at the lows and closed at $1.53 recording a loss of -1.29%. 1,125,035 shares exchanged hands during the trading day. The stock had closed at $1.53 in the previous days trading.
Tokai Pharmaceuticals (TKAI) : The highest level Tokai Pharmaceuticals (TKAI) is projected to reach is $2 for the short term and the lowest estimate is at $1. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $1.68 and the possibility the share price can swing is $0.47.
Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Companys lead drug candidate galeterone is a multi-targeted, oral small molecule drug candidate that has advantages over existing prostate cancer therapies. The Company is focusing its initial development of galeterone on the treatment of patients with castration resistant prostate cancer (CRPC), whose prostate tumor cells express an altered androgen receptor that is truncated. Galeterone acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth. The Company is conducting a Phase II clinical trial of galeterone, known as ARMOR2 trial, for the treatment of multiple CRPC populations.